Soleus Capital Management, L.P. Cerevel Therapeutics Holdings, Inc. Transaction History

Soleus Capital Management, L.P.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2023 Aug 14, 2023	SELL	$23.9 - $35.38 $2.61 Million - $3.86 Million	-109,000 Reduced 70.32%	46,000 $1.46 Million
Q1 2023 May 15, 2023	BUY	$22.82 - $35.32 $3.54 Million - $5.47 Million	155,000 New	155,000 $3.78 Million

242

154M

2.19M

3.87M

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Soleus Capital Management, L.P. with notifications on news.